Wells Fargo
VRDN icon

Wells Fargo’s Viridian Therapeutics VRDN Stock Holding History

Wells Fargo’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,100
Closed -$40.3K – 7288
2024
Q4 		$40.3K Buy
+2,100
New +$45.7K ﹤0.01% 5560

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Wells Fargo's VRDN Position: Q2 2026 in Review

Wells Fargo increased its Viridian Therapeutics (VRDN) stake by 24% in Q2 2026, buying an estimated $360K and bringing the position to 115,563 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3557.

Wells Fargo first reported a position in VRDN in Q3 2017 and has held it in 33 quarters since. The position peaked at $4.58M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Wells Fargo held 115,563 shares of Viridian Therapeutics worth $2.12M as of Q2 2026.
  • Wells Fargo bought 22,359 Viridian Therapeutics shares in Q2 2026, an estimated $360K.
  • Viridian Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3557 holding.
  • Wells Fargo first reported a position in Viridian Therapeutics in Q3 2017 and has held it in 33 quarters since.
  • Wells Fargo's Viridian Therapeutics position peaked at $4.58M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.